Valuation: Spero Therapeutics, Inc.

Market Cap 5.09Cr 4.64Cr 4.29Cr 3.87Cr 7.29Cr 475.62Cr 7.58Cr 52Cr 20Cr 256.72Cr 19Cr 19Cr 810.64Cr P/E 2026 *
-0.68x
P/E 2027 * -2.2x
Enterprise Value 5.09Cr 4.64Cr 4.29Cr 3.87Cr 7.29Cr 475.62Cr 7.58Cr 52Cr 20Cr 256.72Cr 19Cr 19Cr 810.64Cr EV / Sales 2026 *
170x
EV / Sales 2027 * -
Free-Float
77.42%
Yield 2026 *
-
Yield 2027 * -
1 day-3.03%
1 week-14.31%
Current month-17.55%
1 month-20.55%
3 months-27.17%
6 months-66.12%
Current year-62.49%
1 week 0.87
Extreme 0.87
1.04
1 month 0.87
Extreme 0.87
1.24
Current year 0.87
Extreme 0.87
3.08
1 year 0.87
Extreme 0.87
3.08
3 years 0.51
Extreme 0.5052
3.22
5 years 0.51
Extreme 0.5052
16.95
10 years 0.51
Extreme 0.5052
23.64
Manager TitleAgeSince
Chief Executive Officer 47 10/01/2025
Chief Tech/Sci/R&D Officer 69 27/07/2026
Chief Operating Officer 58 01/02/2023
Director TitleAgeSince
Chairman 69 01/01/2014
Chairman 56 10/01/2025
Director/Board Member 73 01/09/2018
Date Insider Type Main position Quantity % Market Cap. Importance
03/08/26 Free

Chief Technology Officer

4,86,986 0.8411%
04/05/26 Sell

Chief Executive Officer

-25,240 0.0436%
06/02/26 Sell

Chief Executive Officer

87,917 0.1560%
Change 5-day change 1-year change 3-year change Capi.($)
-3.03%-14.31%-64.62%-26.55% 5.09Cr
-1.34%-3.09%+56.10%+68.83% 6.55TCr
+0.59%-1.83%+8.98%+90.01% 5.89TCr
+0.54%+0.45%+25.96%+87.77% 5.52TCr
-2.34%-3.90%+10.90%+115.97% 4.61TCr
+0.09%-6.08%+18.67%+25.90% 4.25TCr
-2.58%+0.24%+18.54%+41.28% 3.56TCr
-1.76%-11.56%+126.44%+649.27% 3.46TCr
-0.17%-1.83%+82.46%+57.69% 3.25TCr
-1.69%-0.79%-40.58%+382.68% 2.63TCr
Average -1.17%-4.49%+24.29%+149.28% 4TCr
Weighted average by Cap. -0.83%-3.29%+34.16%+143.39%

Financials

2026 *2027 *
Net sales 3L 3L 3L 2L 4L 2.8Cr 4L 30.55L 12.08L 1.51Cr 11.25L 11.02L 4.78Cr -
Net income -7.47Cr -6.81Cr -6.3Cr -5.68Cr -11Cr -698.04Cr -11Cr -76Cr -30Cr -376.77Cr -28Cr -27Cr -1.19TCr -5.42Cr -4.95Cr -4.57Cr -4.13Cr -7.78Cr -506.95Cr -8.08Cr -55Cr -22Cr -273.63Cr -20Cr -20Cr -864.04Cr
Net Debt - -
Projected Income Statement - Annual - Spero Therapeutics, Inc.
Logo Spero Therapeutics, Inc.
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
Employees
25
Date Price Change Volume
18/26/18 $0.8740 -3.03% 2,73,022
17/26/17 $0.9013 -4.77% 3,32,475
16/26/16 $0.9464 -5.35% 5,94,675
13/26/13 $0.9999 -0.01% 3,57,688
12/26/12 $1.000 -1.96% 3,28,412
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Spero Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.8740USD
Average target price
5.333USD
Spread / Average Target
+510.22%
  1. Stock Market
  2. Stocks
  3. SPRO Stock